Teva Launches Multi-Tranche Senior Notes Offering to Refinance Debt
TEVA sits 99% above its 52-week low of $18.21.
Summary
Teva filed a preliminary prospectus supplement for a multi-tranche senior notes offering (EUR and USD) to fund conditional redemptions of existing higher-coupon debt, extending maturities and managing its capital structure.
Key Events · Financing and Capital Events · TEVA
-
Multi-Tranche Senior Notes Offering
Teva's Dutch finance subsidiaries (II, III, IV) are offering five series of senior notes: EUR notes due 2033 and 2036, and USD notes due 2032, 2034, and 2037. Amounts and coupons are not yet priced.
-
Conditional Redemptions of Existing Debt
Proceeds will fund redemptions of all outstanding 6.750% 2028 USD Notes, 7.875% 2029 USD Notes, 7.375% 2029 Euro Notes, up to $450M of 4.750% 2027 USD Notes, and up to €1,250M of 4.375% 2030 Euro Notes.
-
Debt Maturity Extension
The new notes mature between 2032 and 2037, replacing near-term maturities (2027-2029) and extending Teva's debt runway. The offering is conditioned on the redemptions, but the redemptions are not conditioned on the offering.
-
Underwriting Syndicate
BNP Paribas, Citigroup, Goldman Sachs, and J.P. Morgan are active joint book-running managers, with BofA, HSBC, and Mizuho as passive book-runners.
Analysis · TEVA · Life Sciences
Teva is issuing new senior notes across five tranches (EUR and USD) through its Dutch finance subsidiaries, with proceeds earmarked to redeem existing higher-coupon debt. The conditional redemptions target up to $450M of 2027 USD Notes and up to €1,250M of 2030 Euro Notes, plus all outstanding 2028 and 2029 notes. This is a liability management exercise: Teva is replacing near-term maturities with longer-dated paper, extending its debt runway. The offering is preliminary — pricing and final amounts are not yet set. For a company with $16.65B of senior unsecured debt, this refinancing is material to its capital structure and interest expense trajectory.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TEVA was trading at $36.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $42.1B. The 52-week trading range was $18.21 to $38.37. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.